Astal Laboratories Limited (BOM:512600)
India · Delayed Price · Currency is INR 81.70
+3.18 (4.05%)
At close: Aug 21, 2026
Astal Laboratories Balance Sheet
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Assets
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Equivalents | - | 13.01 | 17.3 | 60.77 | 0.84 | 0.18 |
Loans & Lease Receivables | - | 40.93 | 40.93 | 39.93 | 37.88 | 51.12 |
Other Receivables | - | 1,563 | 276.64 | 158.15 | 31.87 | - |
Property, Plant & Equipment | - | 644.6 | 114.44 | 6.9 | 0.06 | 0.14 |
Goodwill | - | 2,032 | - | - | - | - |
Other Current Assets | - | 183.27 | 14.85 | 37.79 | 28.43 | 0.79 |
Long-Term Deferred Tax Assets | - | - | - | - | 0.01 | 0.07 |
Other Long-Term Assets | - | 29.43 | 21.65 | 52.03 | - | - |
Total Assets | - | 5,182 | 633.41 | 366.13 | 99.08 | 52.29 |
Liabilities
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Accounts Payable | - | 1,238 | 107.75 | 115.15 | 37.93 | - |
Accrued Expenses | - | - | 0.41 | 0.55 | 0.42 | - |
Current Portion of Long-Term Debt | - | 304.42 | 128.12 | 0.55 | - | - |
Current Portion of Leases | - | 1.62 | - | - | - | - |
Long-Term Debt | - | 186.42 | 4.56 | 2.57 | - | - |
Long-Term Leases | - | 6.48 | - | - | - | - |
Current Income Taxes Payable | - | - | 31.31 | 3.82 | - | - |
Other Current Liabilities | - | 98.78 | 0.12 | 10.03 | 8.96 | 0.69 |
Long-Term Deferred Tax Liabilities | - | 8.62 | 1.19 | 0.07 | - | - |
Other Long-Term Liabilities | - | 0 | - | - | - | 0 |
Total Liabilities | - | 1,844 | 273.46 | 132.74 | 47.31 | 0.69 |
Shareholders' Equity
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Common Stock | - | 422.31 | 98.3 | 98.3 | 39.74 | 39.74 |
Additional Paid-In Capital | - | - | 115.22 | 115.22 | - | - |
Retained Earnings | - | - | 107.05 | 17.79 | 9.95 | 9.78 |
Comprehensive Income & Other | - | 2,915 | 39.38 | 2.08 | 2.08 | 2.08 |
Shareholders' Equity | 3,338 | 3,338 | 359.95 | 233.4 | 51.77 | 51.6 |
Total Liabilities & Equity | - | 5,182 | 633.41 | 366.13 | 99.08 | 52.29 |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Total Debt | 498.93 | 498.93 | 132.68 | 3.12 | - | - |
Net Cash (Debt) | -485.92 | -485.92 | -115.38 | 57.64 | 0.84 | 0.18 |
Net Cash Growth | - | - | - | 6729.74% | 361.20% | -41.52% |
Net Cash Per Share | -11.59 | -14.24 | -10.40 | 11.41 | 0.21 | 0.05 |
Filing Date Shares Outstanding | 43.06 | 266.66 | 9.83 | 9.83 | 3.97 | 3.97 |
Total Common Shares Outstanding | 43.06 | 266.66 | 9.83 | 9.83 | 3.97 | 3.97 |
Working Capital | - | 833.04 | 229.61 | 177.12 | 51.7 | 51.4 |
Book Value Per Share | 12.52 | 12.52 | 36.62 | 23.74 | 13.03 | 12.98 |
Tangible Book Value | 1,306 | 1,306 | 359.95 | 233.4 | 51.77 | 51.6 |
Tangible Book Value Per Share | 4.90 | 4.90 | 36.62 | 23.74 | 13.03 | 12.98 |